Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors

作     者：Awadhesh Kumar Singh Ritu Singh 

作者机构：Department of Diabetes&EndocrinologyG.D Hospital&Diabetes InstituteKolkata 700013West BengalIndia 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2022年第13卷第6期

页      面：466-470页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学] 

主　　题：DPP-4 inhibitors SGLT-2 inhibitors GLP-1 receptor agonists Cardiovascular outcomes Renal outcomes 

摘      要：SGLT-2 inhibitors(SGLT-2Is)have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases,heart failure,and diabetic kidney ***,GLP-1 receptor agonists(GLP-1RAs)have significantly improved atherosclerotic cardiovascular *** this end,DPP-4 inhibitors(DPP-4Is)are cardiac-neutral *** long-acting GLP-1RAs have shown a favorable HbA1c lowering compared to DPP-4Is,there is no clinically meaningful HbA1c lowering difference between SGLT-2Is vs ***,the glucose-lowering potential of SGLT-2Is gets compromised with a progressive decline in renal functions,unlike ***,the HbA1c lowering potential of DPP-4Is is favorable in people with T2DM having a modest baseline HbA1c(8.0%-8.5%)compared with SGLT-2Is which lowers HbA1c larger in a background of higher baseline HbA1c(8.5%-9.0%).These findings suggest that the role of DPP-4Is in the management of type 2 diabetes mellitus cannot be completely ignored even in the era of SGLT-2Is.